Estrella Immunopharma (ESLA) Financial Statements
Estrella Immunopharma Financial Overview
Estrella Immunopharma's market cap is currently $27.81M. The company's EPS TTM is $-0.25; its P/E ratio is -2.60; Estrella Immunopharma is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Jun 24 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -13.06M | $ -8.85M | $ -7.31M | $ -11.11M | $ -1.69M |
| EBITDA | $ -13.06M | $ -8.85M | $ -7.31M | $ -11.11M | $ -1.69M |
| Net Income | $ -13.06M | $ -8.85M | $ -7.31M | $ -11.11M | $ -1.69M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.38M | $ 916.92K | $ 4.17M | $ 40.80K | $ 4.09M |
| Total Assets | $ 3.18M | $ 3.14M | $ 4.45M | $ 9.99M | $ 4.92M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 498.60K | $ 0.00 |
| Net Debt | $ -1.38M | $ -916.92K | $ -4.17M | $ 457.80K | $ -4.09M |
| Total Liabilities | $ 13.54M | $ 3.00M | $ 180.70K | $ 2.92M | $ 5.96M |
| Stockholders' Equity | $ -10.37M | $ 143.73K | $ 4.27M | $ 7.07M | $ -1.04M |
| Cash Flow | |||||
| Free Cash Flow | $ -1.79M | $ -3.11M | $ -16.07M | $ -1.04M | $ -1.44M |
| Operating Cash Flow | $ -1.79M | $ -3.11M | $ -16.07M | $ -1.04M | $ -1.44M |
| Investing Cash Flow | $ 0.00 | $ 0.00 | $ 4.96M | $ 36.17M | $ 0.00 |
| Financing Cash Flow | $ 2.25M | $ -134.99K | $ 12.79M | $ -35.56M | $ 5.53M |
Currency in USD